Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Drug Abuse Testing Market Analysis

ID: MRFR/Pharma/1398-CR
92 Pages
Nidhi Mandole
July 2025

Drug of Abuse Testing Market Research Report By Test Type (Urine Testing, Blood Testing, Saliva Testing, Hair Testing), By Methodology (Immunoassays, Chromatography, Spectrometry), By End Use (Hospitals, Laboratories, Workplaces, Home Care), By Substance Tested (Cannabis, Cocaine, Opiates, Amphetamines, Phencyclidine) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Drug Abuse Testing Market Infographic
Purchase Options

Market Analysis

In-depth Analysis of Drug Abuse Testing Market Industry Landscape

Dynamic trends in the drug of abuse testing market have been determined by societal concerns, regulatory developments as well as advances in testing technologies. It is noted that technological innovation has a significant influence on dynamics within the drug of abuse testing Market. The advancement in rapid and accurate testing methods such as urine, saliva, blood and hair tests has transformed the landscape for drugs test. This is made possible by innovations like point-of-care, laboratory automation plus other processes that provide quick and reliable results. Societal concerns about substance abuse and its impact on public health and safety are important factors driving growth and dynamics within the drug of abuse testing market. Consequently, employers conduct screening programs among their employees to ensure that they refrain from abusing drugs while at work which also helps them maintain safe working environments besides supporting rehabilitation efforts. Workplace drug test guidelines are strict regulations governing clinical tests as well as forensic tests due to ethical standards accuracy reliability compliance with regulatory requirements is crucial for market approval user confidence creation leading adoption tech will be influenced by evolving regulations. Market dynamics relating to economies can therefore contribute either towards cost-effectiveness or inefficiency of any program for addressing issues concerning drugs. Employers assess economic benefits associated with per capita income, healthcare expenditures, and property crimes when deciding whether to adopt drug testing programs in workplaces. Drug testing kits’ prices and ease of availability affects their uptake thereby influencing market trends across the globe.

Competition among key market players drives the dynamics operating within the drug of abuse testing market. Differentiation of products and services by companies are anchored on factors such as testing accuracy, detection capabilities for a broad range of substances, simplicity or compatibility with evolving drug trends. Research efforts have put a particular emphasis on developing test technology that is sensitive or detecting new classes of compounds while expanding the detectable spectrum. The COVID-19 pandemic has influenced the drug of abuse testing market dynamics through raising awareness regarding how health is interconnected to well-being. In terms of healthcare delivery via telehealth/telemedicine channels it has made us think about using virtual technology platforms as part-and-parcel our existing drug-testing programs. The role played by the virus in changing mental stability together with shifts in substance use patterns has pointed out why there ought to be policies that promote drugs tests at medical facilities.

Author
Author Profile
Nidhi Mandole
Senior Research Analyst

She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Leave a Comment

FAQs

What is the current valuation of the Drug of Abuse Testing Market?

<p>The Drug of Abuse Testing Market was valued at 4.92 USD Billion in 2024.</p>

What is the projected market size for the Drug of Abuse Testing Market by 2035?

<p>The market is projected to reach 8.197 USD Billion by 2035.</p>

What is the expected CAGR for the Drug of Abuse Testing Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the market during 2025 - 2035 is 4.75%.</p>

Which companies are considered key players in the Drug of Abuse Testing Market?

<p>Key players include Abbott Laboratories, Thermo Fisher Scientific, Quest Diagnostics, and Roche Diagnostics.</p>

What are the primary testing methods used in the Drug of Abuse Testing Market?

<p>The primary testing methods include immunoassays, chromatography, and spectrometry.</p>

How does urine testing compare to blood testing in terms of market valuation?

<p>Urine testing was valued at 1.96 USD Billion in 2024 and is projected to grow to 3.25 USD Billion by 2035, while blood testing was valued at 1.25 USD Billion and is expected to reach 2.0 USD Billion.</p>

What is the market valuation for saliva testing and hair testing in 2024?

<p>Saliva testing was valued at 0.75 USD Billion and hair testing at 0.96 USD Billion in 2024.</p>

Which end-use segment is expected to see the highest growth in the Drug of Abuse Testing Market?

<p>The hospitals segment, valued at 1.476 USD Billion in 2024, is projected to grow to 2.5 USD Billion by 2035.</p>

What substances are primarily tested in the Drug of Abuse Testing Market?

<p>The primary substances tested include cannabis, cocaine, opiates, and amphetamines.</p>

What is the projected market valuation for cannabis testing by 2035?

<p>Cannabis testing is projected to grow from 1.5 USD Billion in 2024 to 2.5 USD Billion by 2035.</p>

Market Summary

As per Market Research Future analysis, the Drug of Abuse Testing Market was estimated at 4.92 USD Billion in 2024. The Drug of Abuse Testing industry is projected to grow from 5.154 USD Billion in 2025 to 8.197 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.75% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Drug of Abuse Testing Market is experiencing robust growth driven by technological advancements and increasing awareness.

  • Technological advancements in testing methods are enhancing the accuracy and efficiency of drug testing. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in drug of abuse testing. Urine testing continues to dominate the market, whereas blood testing is witnessing rapid growth due to its accuracy. The rising substance abuse rates and regulatory compliance requirements are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 4.92 (USD Billion)
2035 Market Size 8.197 (USD Billion)
CAGR (2025 - 2035) 4.75%
Largest Regional Market Share in 2024 North America

Major Players

Abbott Laboratories (US), <a href="https://www.thermofisher.com/in/en/home/clinical/diagnostic-testing/clinical-chemistry-drug-toxicology-testing/drugs-abuse-testing.html">Thermo Fisher Scientific</a> (US), Quest Diagnostics (US), Alere Inc. (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Labcorp (US), Medtox Scientific (US), Psychemedics Corporation (US)

Market Trends

The Drug of Abuse Testing Market is currently experiencing a notable evolution, driven by increasing awareness regarding substance abuse and the necessity for effective monitoring solutions. This market encompasses a variety of testing methods, including urine, saliva, hair, and blood tests, each offering distinct advantages and limitations. The growing prevalence of drug abuse, coupled with stringent regulations and workplace policies, has led to a heightened demand for reliable testing services. Furthermore, advancements in technology are facilitating the development of more accurate and rapid testing methods, which may enhance the overall efficiency of drug screening processes. In addition, the Drug of Abuse Testing Market is witnessing a shift towards more comprehensive testing panels that can detect a wider range of substances. This trend appears to be influenced by the evolving landscape of drug use, where new synthetic drugs and substances are emerging. As a result, organizations and healthcare providers are increasingly seeking testing solutions that can adapt to these changes. Moreover, the integration of testing services with digital platforms for better data management and reporting is likely to shape the future of this market, making it more accessible and user-friendly for various stakeholders.

Technological Advancements in Testing Methods

The Drug of Abuse Testing Market is seeing a surge in innovative technologies that enhance testing accuracy and speed. New methodologies, such as point-of-care testing and mobile applications, are emerging, allowing for immediate results and streamlined processes. These advancements may lead to increased adoption rates among healthcare providers and employers.

Expansion of Testing Panels

There is a growing trend towards the expansion of drug testing panels to include a broader spectrum of substances. This shift is likely driven by the need to address the rising prevalence of new psychoactive substances. Organizations are increasingly recognizing the importance of comprehensive testing to ensure workplace safety and compliance.

Integration of Digital Solutions

The integration of digital solutions into the Drug of Abuse Testing Market is becoming more prevalent. Digital platforms for data management and reporting are enhancing the efficiency of testing processes. This trend may facilitate better tracking of testing outcomes and improve overall accessibility for users.

Drug Abuse Testing Market Market Drivers

Increasing Substance Abuse Rates

The rising rates of substance abuse across various demographics appear to be a primary driver for the Drug of Abuse Testing Market. Reports indicate that the prevalence of drug use has escalated, particularly among young adults and adolescents. This trend necessitates more comprehensive testing solutions to address the growing concern of addiction and its societal impacts. As a result, healthcare providers, employers, and educational institutions are increasingly investing in drug testing programs to ensure safety and compliance. The market is projected to witness substantial growth, with estimates suggesting a compound annual growth rate of over 7% in the coming years, driven by the urgent need for effective drug monitoring and prevention strategies.

Regulatory Compliance and Workplace Safety

Regulatory compliance remains a crucial factor influencing the Drug of Abuse Testing Market. Governments and regulatory bodies have established stringent guidelines for drug testing in various sectors, particularly in transportation, healthcare, and manufacturing. These regulations mandate regular testing to ensure workplace safety and reduce liability risks. Organizations are compelled to implement drug testing protocols to comply with these regulations, thereby driving demand for testing services and products. The market is likely to expand as companies seek to mitigate risks associated with substance abuse among employees, with a notable increase in the adoption of rapid testing methods that provide immediate results.

Rising Awareness of Drug Abuse Consequences

The increasing awareness of the consequences of drug abuse is driving the Drug of Abuse Testing Market. Educational campaigns and public health initiatives are effectively informing communities about the dangers of substance misuse. This heightened awareness is prompting individuals and organizations to prioritize drug testing as a preventive measure. Schools, workplaces, and rehabilitation centers are increasingly implementing drug testing programs to identify and address substance abuse issues early. The market is expected to grow as more stakeholders recognize the importance of proactive measures in combating drug-related problems, leading to a surge in demand for testing services.

Technological Innovations in Testing Solutions

Technological advancements in testing methodologies are reshaping the Drug of Abuse Testing Market. Innovations such as point-of-care testing, mobile testing units, and advanced analytical techniques are enhancing the accuracy and efficiency of drug testing. These technologies not only reduce the time required for results but also improve the overall user experience. The integration of artificial intelligence and machine learning in data analysis is further streamlining testing processes. As these technologies become more accessible, organizations are likely to adopt them, leading to a more robust market. The introduction of non-invasive testing methods, such as saliva and sweat tests, is also expected to contribute to market growth.

Expansion of Drug Testing in Healthcare Settings

The expansion of drug testing in healthcare settings is a notable driver for the Drug of Abuse Testing Market. Healthcare providers are increasingly recognizing the importance of drug testing in managing patient care, particularly in pain management and addiction treatment. The integration of drug testing into routine medical assessments allows for better monitoring of patient compliance and the identification of potential substance abuse issues. As healthcare systems evolve, the demand for comprehensive drug testing solutions is likely to rise. This trend is expected to contribute to market growth, as healthcare facilities seek to enhance patient safety and treatment outcomes through effective drug monitoring.

Market Segment Insights

By Test Type: Urine Testing (Largest) vs. Blood Testing (Fastest-Growing)

In the Drug of Abuse Testing Market, urine testing remains the dominant method, being widely utilized due to its ease of use and cost-effectiveness. It commands a significant share of the market as it is commonly employed in workplace screenings and legal settings. In contrast, although blood testing holds a smaller market share, it is gaining traction among healthcare providers for its accuracy and immediacy in detecting substance use, leading to faster patient care decisions.

Urine Testing: Dominant vs. Blood Testing: Emerging

Urine testing stands out as the established leader in the Drug of Abuse Testing Market, primarily due to its widespread acceptance and lower testing costs. This method offers quick results and is less invasive, making it the preferred choice in employment screenings and court-mandated testing. Conversely, blood testing is emerging as an alternative that appeals to medical professionals who prioritize accuracy and real-time results. It is increasingly viewed as a sophisticated option for detecting recent substance use, making it relevant for clinical settings. As awareness of the advantages of blood testing rises, its adoption is projected to gain momentum in the coming years.

By Methodology: Immunoassays (Largest) vs. Chromatography (Fastest-Growing)

In the Drug of Abuse Testing Market, the methodology segment is primarily dominated by <a href="https://www.marketresearchfuture.com/reports/immunoassays-market-10081">immunoassays</a>, known for their high sensitivity and ease of use. <a href="https://www.marketresearchfuture.com/reports/immunoassay-market-5841">Immunoassays </a>account for a significant share due to their widespread application in initial screenings, making them the go-to choice for testing in various settings. Meanwhile, chromatography, although smaller in market share, is gaining traction among laboratories that require accurate confirmation of drug presence, thus showing strong growth potential. Growth trends indicate a notable shift toward chromatographic methods as regulations concerning drug testing become more stringent. The increased frequency of drug testing in corporate and clinical environments is also driving the demand towards more sophisticated techniques, thereby fostering rapid advancements and adoption of chromatography as a vital tool in comprehensive drug detection.

Methodology: Immunoassays (Dominant) vs. Chromatography (Emerging)

Immunoassays are recognized as a dominant methodology in the Drug of Abuse Testing Market, characterized by their cost-effectiveness and rapid results. They facilitate large-scale screening processes, making them indispensable for organizations that prioritize prompt drug assessments. In contrast, <a href="https://www.marketresearchfuture.com/reports/chromatography-systems-market-2324">chromatography </a>is increasingly being viewed as an emerging methodology, esteemed for its precision and ability to analyze complex matrices. While chromatography may require more time and advanced technical expertise, its robust validation and reliability make it essential for confirming positive test results obtained from immunoassays. As regulations tighten and the need for accuracy grows, the placement of chromatography as a companion technique alongside immunoassays is crucial for comprehensive drug testing solutions.

By End Use: Hospitals (Largest) vs. Workplaces (Fastest-Growing)

In the Drug of Abuse Testing Market, the end use segment is divided into Hospitals, Laboratories, Workplaces, and Home Care. Hospitals currently hold the largest share, attributing to their extensive patient management and need for comprehensive drug testing protocols. Laboratories are also significant players, supporting hospitals and workplaces alike. Workplaces are gaining momentum, with increasing emphasis on employee wellness programs. Home Care is a smaller but equally essential segment, catering to individuals needing discreet testing solutions.

Hospitals (Dominant) vs. Workplaces (Emerging)

Hospitals serve as the dominant segment in the Drug of Abuse Testing Market due to their critical role in patient diagnostics and treatment protocols. They are equipped with advanced technologies and skilled personnel, ensuring accurate and timely results. In contrast, the Workplace segment is emerging rapidly, driven by rising awareness about substance abuse and the implementation of drug testing policies to enhance employee safety and productivity. The increasing number of employers adopting drug screening standards reflects a growing trend towards creating healthier work environments. As a response to such policy shifts, both segments are likely to adapt, innovate, and continue their evolution within the market.

By Substance Tested: Cannabis (Largest) vs. Cocaine (Fastest-Growing)

In the Drug of Abuse Testing Market, the segment values of Cannabis, Cocaine, Opiates, Amphetamines, and Phencyclidine are distributed in a way that highlights Cannabis as the largest share holder. Cannabis remains the most tested substance, driven by its prevalent usage across various demographics. Meanwhile, Cocaine holds the position as the fastest-growing segment, reflecting changing social attitudes and increasing usage among certain populations. Although Opiates and Amphetamines hold significant shares, their growth rates lag behind that of Cocaine. Examining growth trends, the rising preference for casual cannabis use, legalization movements, and increased awareness around drug testing are key drivers for Cannabis testing. In contrast, Cocaine's increased testing is propelled by a resurgence in usage rates and heightened regulatory scrutiny. Factors such as public health initiatives and workplace policies are expected to further drive testing for both substances as the market continues to evolve, making these segments critical areas to watch in the future.

Cannabis (Dominant) vs. Cocaine (Emerging)

Cannabis continues to dominate the Drug of Abuse Testing Market due to its widespread acceptance and usage across various age groups. Its prevalence in both recreational and medicinal contexts makes it a staple in drug testing protocols. As legislation around cannabis usage evolves, including legalization in many regions, the testing for cannabis remains essential for compliance and safety measures in employment and healthcare. In contrast, Cocaine represents an emerging segment that has recently seen an uptick in testing. This change is attributed to increasing cocaine use amid shifting social landscapes and greater public acknowledgment of substance abuse issues. Consequently, while Cannabis remains the dominant substance tested, Cocaine's growing market presence necessitates evolving approaches and considerations from testing providers.

Get more detailed insights about Drug of Abuse Testing Market Research Report - Forecast till 2035

Regional Insights

The Drug of Abuse Testing Market is witnessing significant growth across various regions, with a projected value of 4.92 USD Billion in 2024. North America holds the largest share, valued at 2.15 USD Billion, and is expected to rise to 3.48 USD Billion by 2035, showcasing its dominant position in this market due to stringent regulations and a high prevalence of drug abuse issues.

Europe follows as the second-largest market, valued at 1.25 USD Billion in 2024 and expected to reach 2.06 USD Billion, driven by increased awareness and government initiatives focused on drug testing.South America, while smaller at 0.45 USD Billion in 2024, is important as emerging economies are beginning to implement drug testing regulations, projected to grow to 0.78 USD Billion. The Asia Pacific region, valued at 0.95 USD Billion, emphasizes a growing understanding of drug abuse challenges and is expected to expand to 1.57 USD Billion.

Lastly, the Middle East and Africa market, valued at 0.12 USD Billion, is slower to grow, largely due to varying regulatory environments and cultural attitudes towards drug testing, projected to reach 0.21 USD Billion.Overall, this regional segmentation of the Drug of Abuse Testing Market illustrates significant growth potential and varying dynamics influenced by local regulations, awareness, and market drivers.

Key Players and Competitive Insights

The Drug of Abuse Testing Market is characterized by a diverse range of players who develop and offer innovative testing solutions to address the critical need for reliable drug testing methods across various sectors, including healthcare, workplace, and law enforcement. This market is driven by rising concerns regarding substance abuse and its impact on public health and safety. The competitive landscape features both well-established enterprises and emerging companies, each vying for market share through advancements in technology, product differentiation, and strategic partnerships.
Trends such as increased adoption of point-of-care testing, regulatory compliance, and the integration of digital technologies into the testing process are shaping the market dynamics. Companies that effectively leverage these trends while responding to the unique demands of different regions are positioned to gain a competitive edge.F. HoffmannLa Roche has established itself as a prominent player in the Drug of Abuse Testing Market, recognized for its strong emphasis on research and development, coupled with its commitment to high-quality standards. The company has a robust portfolio of drug testing products, which includes sophisticated immunoassay tests and molecular diagnostic solutions.
Its expertise in pharmaceuticals and diagnostics enables F. HoffmannLa Roche to develop comprehensive testing methodologies that cater to various applications such as clinical laboratories and toxicology screenings. The organization’s global presence further strengthens its market position, allowing it to distribute its innovative products and services across a wide range of geographical markets.
The company's investment in cutting-edge technology and a deep understanding of regulatory processes contribute significantly to its strengths in maintaining a competitive advantage in the drug testing arena.Sonic Healthcare is a key entity within the Drug of Abuse Testing Market, known for its extensive laboratory services and commitment to quality and accuracy in test results. The company excels in providing a broad array of services, including drug and alcohol testing, tailored to meet the needs of both private and public sectors on a global scale.
Sonic Healthcare stands out due to its streamlined operations, advanced laboratory capabilities, and a strong focus on customer service, which collectively enhance its market presence. The company’s global reach is augmented by strategic mergers and acquisitions that allow it to expand its service offerings and enhance its technological infrastructure. Key products/services offered by Sonic Healthcare are designed to ensure fast turnaround times for results, and this efficiency is particularly valued in the workplace and legal environments. Their commitment to continuous improvement and adaptation in testing methodologies helps solidify their position as a leading provider in the global arena.

Key Companies in the Drug Abuse Testing Market include

Industry Developments

Recent developments in the Drug of Abuse Testing Market indicate a growing emphasis on innovation and expansion among leading players. In mid-2024, Premier Biotech expanded its testing portfolio by acquiring Desert Tox, a SAMHSA-certified laboratory, thereby improving its clinical and forensic capabilities. An comprehensive 88-compound NPS urine panel was introduced by Quest Diagnostics in late 2023 to enhance the detection of emergent synthetic drugs. 

Thermo Fisher introduced a mass spectrometry-based platform with high sensitivity in November 2023, which enhanced the speed and precision of forensic and clinical examinations. With the integration of AI and mobile/cloud-based data systems to improve accuracy and accessibility, the broader industry is continuing to transition to point-of-care and non-invasive testing formats, including saliva, hair, and perspiration. 

Geographically, North America maintains its leadership in terms of regulatory frameworks, while Asia-Pacific is the leader in terms of growth as a result of the increasing awareness of substance use and rise in workplace safety mandates. In general, the global market was valued at approximately US$6.7 billion between 2022 and 2023. It is anticipated that this figure will nearly double by 2032, with a robust 5–7% compound annual growth rate.

Future Outlook

Drug Abuse Testing Market Future Outlook

The Drug of Abuse Testing Market is projected to grow at a 4.75% CAGR from 2025 to 2035, driven by increasing regulatory requirements and rising awareness of substance abuse.

New opportunities lie in:

  • Development of mobile testing units for remote areas
  • Integration of AI for predictive analytics in testing
  • Expansion of testing services in corporate wellness programs

By 2035, the market is expected to be robust, driven by innovation and expanded service offerings.

Market Segmentation

Drug Abuse Testing Market End Use Outlook

  • Hospitals
  • Laboratories
  • Workplaces
  • Home Care

Drug Abuse Testing Market Test Type Outlook

  • Urine Testing
  • Blood Testing
  • Saliva Testing
  • Hair Testing

Drug Abuse Testing Market Methodology Outlook

  • Immunoassays
  • Chromatography
  • Spectrometry

Drug Abuse Testing Market Substance Tested Outlook

  • Cannabis
  • Cocaine
  • Opiates
  • Amphetamines
  • Phencyclidine

Report Scope

MARKET SIZE 2024 4.92(USD Billion)
MARKET SIZE 2025 5.154(USD Billion)
MARKET SIZE 2035 8.197(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.75% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Abbott Laboratories (US), Thermo Fisher Scientific (US), Quest Diagnostics (US), Alere Inc. (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Labcorp (US), Medtox Scientific (US), Psychemedics Corporation (US)
Segments Covered Test Type, Methodology, End Use, Substance Tested, Regional
Key Market Opportunities Integration of advanced technologies enhances accuracy and efficiency in the Drug of Abuse Testing Market.
Key Market Dynamics Rising regulatory scrutiny and technological advancements drive innovation in the Drug of Abuse Testing Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Drug of Abuse Testing Market?

<p>The Drug of Abuse Testing Market was valued at 4.92 USD Billion in 2024.</p>

What is the projected market size for the Drug of Abuse Testing Market by 2035?

<p>The market is projected to reach 8.197 USD Billion by 2035.</p>

What is the expected CAGR for the Drug of Abuse Testing Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the market during 2025 - 2035 is 4.75%.</p>

Which companies are considered key players in the Drug of Abuse Testing Market?

<p>Key players include Abbott Laboratories, Thermo Fisher Scientific, Quest Diagnostics, and Roche Diagnostics.</p>

What are the primary testing methods used in the Drug of Abuse Testing Market?

<p>The primary testing methods include immunoassays, chromatography, and spectrometry.</p>

How does urine testing compare to blood testing in terms of market valuation?

<p>Urine testing was valued at 1.96 USD Billion in 2024 and is projected to grow to 3.25 USD Billion by 2035, while blood testing was valued at 1.25 USD Billion and is expected to reach 2.0 USD Billion.</p>

What is the market valuation for saliva testing and hair testing in 2024?

<p>Saliva testing was valued at 0.75 USD Billion and hair testing at 0.96 USD Billion in 2024.</p>

Which end-use segment is expected to see the highest growth in the Drug of Abuse Testing Market?

<p>The hospitals segment, valued at 1.476 USD Billion in 2024, is projected to grow to 2.5 USD Billion by 2035.</p>

What substances are primarily tested in the Drug of Abuse Testing Market?

<p>The primary substances tested include cannabis, cocaine, opiates, and amphetamines.</p>

What is the projected market valuation for cannabis testing by 2035?

<p>Cannabis testing is projected to grow from 1.5 USD Billion in 2024 to 2.5 USD Billion by 2035.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Test Type (USD Billion)
    2. | | 4.1.1 Urine Testing
    3. | | 4.1.2 Blood Testing
    4. | | 4.1.3 Saliva Testing
    5. | | 4.1.4 Hair Testing
    6. | 4.2 Healthcare, BY Methodology (USD Billion)
    7. | | 4.2.1 Immunoassays
    8. | | 4.2.2 Chromatography
    9. | | 4.2.3 Spectrometry
    10. | 4.3 Healthcare, BY End Use (USD Billion)
    11. | | 4.3.1 Hospitals
    12. | | 4.3.2 Laboratories
    13. | | 4.3.3 Workplaces
    14. | | 4.3.4 Home Care
    15. | 4.4 Healthcare, BY Substance Tested (USD Billion)
    16. | | 4.4.1 Cannabis
    17. | | 4.4.2 Cocaine
    18. | | 4.4.3 Opiates
    19. | | 4.4.4 Amphetamines
    20. | | 4.4.5 Phencyclidine
    21. | 4.5 Healthcare, BY Region (USD Billion)
    22. | | 4.5.1 North America
    23. | | | 4.5.1.1 US
    24. | | | 4.5.1.2 Canada
    25. | | 4.5.2 Europe
    26. | | | 4.5.2.1 Germany
    27. | | | 4.5.2.2 UK
    28. | | | 4.5.2.3 France
    29. | | | 4.5.2.4 Russia
    30. | | | 4.5.2.5 Italy
    31. | | | 4.5.2.6 Spain
    32. | | | 4.5.2.7 Rest of Europe
    33. | | 4.5.3 APAC
    34. | | | 4.5.3.1 China
    35. | | | 4.5.3.2 India
    36. | | | 4.5.3.3 Japan
    37. | | | 4.5.3.4 South Korea
    38. | | | 4.5.3.5 Malaysia
    39. | | | 4.5.3.6 Thailand
    40. | | | 4.5.3.7 Indonesia
    41. | | | 4.5.3.8 Rest of APAC
    42. | | 4.5.4 South America
    43. | | | 4.5.4.1 Brazil
    44. | | | 4.5.4.2 Mexico
    45. | | | 4.5.4.3 Argentina
    46. | | | 4.5.4.4 Rest of South America
    47. | | 4.5.5 MEA
    48. | | | 4.5.5.1 GCC Countries
    49. | | | 4.5.5.2 South Africa
    50. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Abbott Laboratories (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Thermo Fisher Scientific (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Quest Diagnostics (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Alere Inc. (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Roche Diagnostics (CH)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Siemens Healthineers (DE)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Labcorp (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Medtox Scientific (US)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Psychemedics Corporation (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TEST TYPE
    4. | 6.4 US MARKET ANALYSIS BY METHODOLOGY
    5. | 6.5 US MARKET ANALYSIS BY END USE
    6. | 6.6 US MARKET ANALYSIS BY SUBSTANCE TESTED
    7. | 6.7 CANADA MARKET ANALYSIS BY TEST TYPE
    8. | 6.8 CANADA MARKET ANALYSIS BY METHODOLOGY
    9. | 6.9 CANADA MARKET ANALYSIS BY END USE
    10. | 6.10 CANADA MARKET ANALYSIS BY SUBSTANCE TESTED
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE
    13. | 6.13 GERMANY MARKET ANALYSIS BY METHODOLOGY
    14. | 6.14 GERMANY MARKET ANALYSIS BY END USE
    15. | 6.15 GERMANY MARKET ANALYSIS BY SUBSTANCE TESTED
    16. | 6.16 UK MARKET ANALYSIS BY TEST TYPE
    17. | 6.17 UK MARKET ANALYSIS BY METHODOLOGY
    18. | 6.18 UK MARKET ANALYSIS BY END USE
    19. | 6.19 UK MARKET ANALYSIS BY SUBSTANCE TESTED
    20. | 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE
    21. | 6.21 FRANCE MARKET ANALYSIS BY METHODOLOGY
    22. | 6.22 FRANCE MARKET ANALYSIS BY END USE
    23. | 6.23 FRANCE MARKET ANALYSIS BY SUBSTANCE TESTED
    24. | 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE
    25. | 6.25 RUSSIA MARKET ANALYSIS BY METHODOLOGY
    26. | 6.26 RUSSIA MARKET ANALYSIS BY END USE
    27. | 6.27 RUSSIA MARKET ANALYSIS BY SUBSTANCE TESTED
    28. | 6.28 ITALY MARKET ANALYSIS BY TEST TYPE
    29. | 6.29 ITALY MARKET ANALYSIS BY METHODOLOGY
    30. | 6.30 ITALY MARKET ANALYSIS BY END USE
    31. | 6.31 ITALY MARKET ANALYSIS BY SUBSTANCE TESTED
    32. | 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE
    33. | 6.33 SPAIN MARKET ANALYSIS BY METHODOLOGY
    34. | 6.34 SPAIN MARKET ANALYSIS BY END USE
    35. | 6.35 SPAIN MARKET ANALYSIS BY SUBSTANCE TESTED
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY METHODOLOGY
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY SUBSTANCE TESTED
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY TEST TYPE
    42. | 6.42 CHINA MARKET ANALYSIS BY METHODOLOGY
    43. | 6.43 CHINA MARKET ANALYSIS BY END USE
    44. | 6.44 CHINA MARKET ANALYSIS BY SUBSTANCE TESTED
    45. | 6.45 INDIA MARKET ANALYSIS BY TEST TYPE
    46. | 6.46 INDIA MARKET ANALYSIS BY METHODOLOGY
    47. | 6.47 INDIA MARKET ANALYSIS BY END USE
    48. | 6.48 INDIA MARKET ANALYSIS BY SUBSTANCE TESTED
    49. | 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE
    50. | 6.50 JAPAN MARKET ANALYSIS BY METHODOLOGY
    51. | 6.51 JAPAN MARKET ANALYSIS BY END USE
    52. | 6.52 JAPAN MARKET ANALYSIS BY SUBSTANCE TESTED
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY METHODOLOGY
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY SUBSTANCE TESTED
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY METHODOLOGY
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY END USE
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY SUBSTANCE TESTED
    61. | 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE
    62. | 6.62 THAILAND MARKET ANALYSIS BY METHODOLOGY
    63. | 6.63 THAILAND MARKET ANALYSIS BY END USE
    64. | 6.64 THAILAND MARKET ANALYSIS BY SUBSTANCE TESTED
    65. | 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE
    66. | 6.66 INDONESIA MARKET ANALYSIS BY METHODOLOGY
    67. | 6.67 INDONESIA MARKET ANALYSIS BY END USE
    68. | 6.68 INDONESIA MARKET ANALYSIS BY SUBSTANCE TESTED
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY METHODOLOGY
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY END USE
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY SUBSTANCE TESTED
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE
    75. | 6.75 BRAZIL MARKET ANALYSIS BY METHODOLOGY
    76. | 6.76 BRAZIL MARKET ANALYSIS BY END USE
    77. | 6.77 BRAZIL MARKET ANALYSIS BY SUBSTANCE TESTED
    78. | 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE
    79. | 6.79 MEXICO MARKET ANALYSIS BY METHODOLOGY
    80. | 6.80 MEXICO MARKET ANALYSIS BY END USE
    81. | 6.81 MEXICO MARKET ANALYSIS BY SUBSTANCE TESTED
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY METHODOLOGY
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY END USE
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY SUBSTANCE TESTED
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY METHODOLOGY
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SUBSTANCE TESTED
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY METHODOLOGY
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY SUBSTANCE TESTED
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY METHODOLOGY
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY SUBSTANCE TESTED
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY METHODOLOGY
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY END USE
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY SUBSTANCE TESTED
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY METHODOLOGY, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY METHODOLOGY, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY SUBSTANCE TESTED, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY SUBSTANCE TESTED, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY END USE, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY END USE, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY END USE, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY END USE, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY END USE, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY END USE, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY END USE, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY END USE, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY END USE, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY END USE, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY END USE, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY END USE, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY END USE, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY END USE, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY END USE, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY END USE, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY END USE, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY END USE, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY END USE, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY END USE, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY END USE, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY END USE, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY END USE, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY END USE, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY END USE, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY END USE, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY END USE, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY END USE, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY METHODOLOGY, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY END USE, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Test Type (USD Billion, 2025-2035)

  • Urine Testing
  • Blood Testing
  • Saliva Testing
  • Hair Testing

Healthcare By Methodology (USD Billion, 2025-2035)

  • Immunoassays
  • Chromatography
  • Spectrometry

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Laboratories
  • Workplaces
  • Home Care

Healthcare By Substance Tested (USD Billion, 2025-2035)

  • Cannabis
  • Cocaine
  • Opiates
  • Amphetamines
  • Phencyclidine
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions
%>